5-ethyl-3,6-dihydro-2H-pyran | 88981-46-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: 5-ethyl-3,6-dihydro-2H-pyran
• 英文别名: 5-Aethyl-3,6-dihydro-2H-pyran；5-Ethyl-3,6-dihydro-2H-pyran
• CAS: 88981-46-8
• 化学式: C₇H₁₂O
• 分子量: 112.172
• InChiKey: NWJRNYAKPORTAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-ethyl-3,6-dihydro-2H-pyran 在 乙醚 、 铂 作用下， 生成 3-ethyl-tetrahydro-pyran
  参考文献：
  名称：

  Colonge; Boisde, Bulletin de la Societe Chimique de France, 1956, p. 824

  摘要：

  DOI：
• 作为产物：
  描述：

  3-ethyl-4-chloro-tetrahydro-pyran 在 氢氧化钾 、 乙二醇 作用下， 生成 5-ethyl-3,6-dihydro-2H-pyran
  参考文献：
  名称：

  Colonge; Boisde, Bulletin de la Societe Chimique de France, 1956, p. 824

  摘要：

  DOI：

文献信息

• Modulators of cystic fibrosis transmembrane conductance regulator
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10758534B2

  公开（公告）日：2020-09-01

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明的特征是一种式 I 的化合物： 或其药学上可接受的盐，其中 R1、R2、R3、W、X、Y、Z、n、o、p 和 q 在此定义，用于治疗 CFTR 介导的疾病，如囊性纤维化。本发明还包括药物组合物、治疗方法及其试剂盒。
• Use of pyridinium chlorochromate as methylene oxidant in 5,6-dihydropyrans: a practical one-step preparation of the anhydromevalonolactone
  作者：Francesco Bonadies、Romano Di Fabio、Carlo Bonini

  DOI：10.1021/jo00183a030

  日期：1984.5
• HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME
  申请人：MILLENNIUM PHARMACEUTICALS, INC.

  公开号：US20160355504A1

  公开（公告）日：2016-12-08

  Disclosed are compounds of formula (I); or a pharmaceutically acceptable salt thereof; wherein Y, Ra, Ra′, Rc, Rf, X2, Rd, Rd′, Re, Re′2, m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders.
• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
  申请人：Miller Mark Thomas

  公开号：US20170196862A2

  公开（公告）日：2017-07-13

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
• US9695154B2
  申请人：——

  公开号：US9695154B2

  公开（公告）日：2017-07-04